SPCEO1 wrote: TH should already know a lot about TH-1902 works. They should have enrolled 35 or so patients by now and around 20 may have gone the full 12 weeks. If the drug is as good as we think it is, it should already be evident even just in these early patients. The company's words and actions also indicate they have a good idea of where TH-1902 is heading. So, it would be helpful if they told us what they have learned so far.
But they may hold back as the info we want to hear now, and which they likely already have, is also key to optimize the future share offering they will need to do to fund the phase 2 trial(s). Since the stock market is in full bear mode right now and a phase 2 is not likely to start until April 2023, TH may decide to hold back that info until right before any share offering is commenced, hopefully under better market conditions and closer to the start of the phase 2.
If that theory is correct, we will get a lot of postive commentary and few hard facts this week.
I am hoping for more info this week but the above is a realistic scenario that would mean more waiting.
Meanwhile, it is apparent from today's low trading volume that we may be the only ones waiting to hear anything TH might say. There is clearly not much anticipation built up for Thursday's reveal, whatever it might be.
Bucknelly21 wrote: It really is time to deliver, they know if it works or not